文献速递糖尿病

在心血管高危的成人1型糖尿病患者中,使用Steno T1风险引擎比使用ESC/EASD-2019能更好地识别临床前动脉粥样硬化

Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk.
PubMed 文献 · Diabetes Care · 2022-01-01

研究连续纳入501例无心血管疾病的1型糖尿病成人患者,评估Steno T1风险引擎与ESC/EASD-2019风险量表的一致性及其与颈动脉斑块检出的关系。两种T1D专用量表一致性差(κ=0.19),Steno-Risk风险类别升高与斑块检出率呈阶梯式增加相关(低危18.4%、中危38.2%、高危64.1%,趋势P<0.001),而ESC/EASD-2019无此差异(P=0.130)。Steno-Risk能识别斑块个体(AUC 0.691,P<0.001),ESC/EASD-2019则不能(AUC 0.538,P=0.149)。

要点

  • Steno-Risk与ESC/EASD-2019在1型糖尿病患者中一致性差(κ=0.19)。
  • Steno-Risk风险类别越高,颈动脉斑块检出率越高(低危18.4%、中危38.2%、高危64.1%),ESC/EASD-2019则无差异。
  • Steno-Risk能识别斑块个体(AUC 0.691,P<0.001),优于ESC/EASD-2019(AUC 0.538,P=0.149)。

核心结论

  • 在行一级预防的1型糖尿病患者中,使用Steno-Risk似乎比使用ESC/EASD-2019能更好地识别有动脉粥样硬化的个体。
  • 颈动脉超声可改善心血管风险分类。

研究设计与样本

  • 连续入选1型糖尿病、无心血管疾病、年龄≥40岁、合并肾病和/或糖尿病病程≥10年且伴另一危险因素的患者。
  • 通过超声测定不同颈动脉节段的斑块。
  • 按ESC/EASD-2019风险组(中/高/极高危)和Steno-Risk(<10%低危;10-20%中危;≥20%高危)评估心血管风险。
  • 探索性分析中,对40-79岁个体评估非T1D专用的2013 ACC/AHA指南汇总队列方程。

主要发现

  • 共纳入501例患者(53%为男性,平均年龄48.8岁,T1D病程中位数26.5年,41.3%存在斑块)。
  • T1D专用量表间一致性差(κ=0.19)。
  • 按Steno-Risk类别,斑块检出率呈阶梯式增加:低危18.4%、中危38.2%、高危64.1%(趋势P<0.001),ESC/EASD-2019则无差异(P=0.130)。
  • Steno-Risk能识别斑块个体(AUC 0.691,P<0.001),ESC/EASD-2019则不能(AUC 0.538,P=0.149)。
  • 多项式回归模型(调整血脂参数和心脏保护治疗)中,无论ESC/EASD-2019类别如何,Steno-Risk高危与动脉粥样硬化直接相关(在ESC/EASD-2019中/高危组,斑块存在和≥2个斑块的OR分别为2.91[95%CI 1.27-6.72]和4.94[2.35-10.40])。

关键数值与推荐

  • ESC/EASD-2019风险组:中危、高危、极高危。
  • Steno-Risk:<10%低危;10-20%中危;≥20%高危。
  • 斑块存在和≥2个斑块的OR分别为2.91(95%CI 1.27-6.72)和4.94(2.35-10.40)。
  • AUC:Steno-Risk 0.691(P<0.001);ESC/EASD-2019 0.538(P=0.149)。
  • 趋势P值:Steno-Risk P<0.001;ESC/EASD-2019 P=0.130。

临床怎么用

  • 在行一级预防的成人1型糖尿病患者中,使用Steno-Risk似乎比使用ESC/EASD-2019能更好地识别有动脉粥样硬化的个体。
  • 颈动脉超声可改善心血管风险分类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the concordance between the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (ESC/EASD-2019) and the Steno T1 Risk Engine (Steno-Risk) cardiovascular risk scales for individuals with type 1 diabetes (T1D) without cardiovascular disease (CVD) and to analyze the relationships of their use with identification of preclinical atherosclerosis. RESEARCH DESIGN AND METHODS: We consecutively selected patients with T1D, without CVD, age ≥40 years, with nephropathy, and/or with ≥10 years of T1D evolution with another risk factor. The presence of plaque at different carotid segments was determined by ultrasonography. Cardiovascular risk was estimated in accord with ESC/EASD-2019 risk groups (moderate/high/very high) and the Steno-Risk (<10%, low; 10-20%, moderate; ≥20%, high), as T1D-specific scores. In an exploratory analysis, we also evaluated the non-T1D-specific 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk (ACC/AHA-2013) pooled cohort equation for individuals between 40 and 79 years of age. RESULTS: We included 501 patients (53% men, mean age 48.8 years, median T1D duration 26.5 years, 41.3% harboring plaques). Concordance between T1D-specific scales was poor (κ = 0.19). A stepped increase in the presence of plaques according to Steno-Risk category was seen (18.4%, 38.2%, and 64.1%, for low, moderate, and high risk, respectively; P for trend <0.001), with no differences according to ESC/EASD-2019 (P = 0.130). Steno-Risk identified individuals with plaques, unlike ESC/EASD-2019 (area under the curve [AUC] 0.691, P < 0.001, vs. AUC 0.538, P = 0.149). Finally, in polynomial regression models (with adjustment for lipid parameters and cardioprotective treatment), irrespective of the ESC/EASD-2019 category, high risk by Steno-Risk was directly associated with atherosclerosis (in moderate/high-risk by ESC/EASD-2019 odds ratio 2.91 [95% CI 1.27-6.72] and 4.94 [2.35-10.40] for the presence of plaque and two or more plaques). Similar results were obtained with discordant higher Steno-Risk versus ACC/AHA-2013 (P < 0.001). CONCLUSIONS: Among T1D patients undergoing primary prevention, use of Steno-Risk seems to result in better recognition of individuals with atherosclerosis in comparison with ESC/EASD-2019. Notwithstanding, carotid ultrasound could improve the categorization of cardiovascular risk.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Serés-Noriega T, Giménez M, Perea V, et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care. 2022. PMID: 35944257. doi:10.2337/dc22-0118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。